Literature DB >> 2006161

Dual site model for the organogenic activity of angiogenin.

T W Hallahan1, R Shapiro, B L Vallee.   

Abstract

The residues that are indispensable for the ribonucleolytic activity of angiogenin are also known to be essential for its angiogenic activity. We now demonstrate that residues in another region of the protein, devoid of catalytic residues, are additionally required for angiogenesis. Endoproteinase Lys-C or a baby hamster kidney cell protease cleaves angiogenin at the peptide bond either between Lys-60 and Asn-61 or between Glu-67 and Asn-68, respectively. The two polypeptide fragments resulting from either cleavage remain linked by disulfide bonds. These two derivatives and des-(Asn61-Glu67)-angiogenin--in which both bonds are cleaved--retain their ribonucleolytic activities toward tRNA, 18S and 28S rRNA, and dinucleoside phosphates but are no longer angiogenic on the chicken embryo chorioallantoic membrane. Further, their capacity to elicit a second messenger response in endothelial cells is greatly decreased. Moreover, none of these three derivatives inhibit angiogenin-induced angiogenesis. This contrasts with two active site mutants of angiogenin. These results identify the residues from 60 to 68 as a region of angiogenin that is part of a cell-surface receptor binding site [see accompanying manuscript: Hu, G.-F., Chang, S.-I., Riordan, J.F. & Vallee, B.L. (1991) Proc. Natl. Acad. Sci. USA 88, 2227-2231] and serve as the basis for a dual site model of the organogenic activity of angiogenin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006161      PMCID: PMC51202          DOI: 10.1073/pnas.88.6.2222

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Characteristic ribonucleolytic activity of human angiogenin.

Authors:  R Shapiro; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1986-06-17       Impact factor: 3.162

2.  A preliminary three-dimensional structure of angiogenin.

Authors:  K A Palmer; H A Scheraga; J F Riordan; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

3.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C.

Authors:  N L Esmon; W G Owen; C T Esmon
Journal:  J Biol Chem       Date:  1982-01-25       Impact factor: 5.157

4.  Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells.

Authors:  J W Fett; D J Strydom; R R Lobb; E M Alderman; J L Bethune; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1985-09-24       Impact factor: 3.162

5.  Amino acid sequence of human tumor derived angiogenin.

Authors:  D J Strydom; J W Fett; R R Lobb; E M Alderman; J L Bethune; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1985-09-24       Impact factor: 3.162

6.  Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor.

Authors:  K Kurachi; E W Davie; D J Strydom; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1985-09-24       Impact factor: 3.162

7.  Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin.

Authors:  R Shapiro; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Angiogenin abolishes cell-free protein synthesis by specific ribonucleolytic inactivation of ribosomes.

Authors:  D K St Clair; S M Rybak; J F Riordan; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  Mutagenesis of aspartic acid-116 enhances the ribonucleolytic activity and angiogenic potency of angiogenin.

Authors:  J W Harper; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

10.  Avascular and vascular phases of tumour growth in the chick embryo.

Authors:  D Knighton; D Ausprunk; D Tapper; J Folkman
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

View more
  35 in total

1.  Structure of murine angiogenin: features of the substrate- and cell-binding regions and prospects for inhibitor-binding studies.

Authors:  Daniel E Holloway; Gayatri B Chavali; Michelle C Hares; Vasanta Subramanian; K Ravi Acharya
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-11-19

2.  Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.

Authors:  A C Papageorgiou; R Shapiro; K R Acharya
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

3.  Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Authors:  Sujoy Dutta; Chirosree Bandyopadhyay; Virginie Bottero; Mohanan V Veettil; Lydia Wilson; Michael R Pins; Karen E Johnson; Case Warshall; Bala Chandran
Journal:  Mol Oncol       Date:  2014-01-04       Impact factor: 6.603

Review 4.  New insights into the role of angiogenin in actin polymerization.

Authors:  Mikhail G Pyatibratov; Alla S Kostyukova
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

5.  A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice.

Authors:  I J Polakowski; M K Lewis; V R Muthukkaruppan; B Erdman; L Kubai; R Auerbach
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Actin is a surface component of calf pulmonary artery endothelial cells in culture.

Authors:  J Moroianu; J W Fett; J F Riordan; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

7.  Angiogenin supports endothelial and fibroblast cell adhesion.

Authors:  F Soncin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

Review 8.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

9.  Mutational dynamics of murine angiogenin duplicates.

Authors:  Francisco M Codoñer; Silvia Alfonso-Loeches; Mario A Fares
Journal:  BMC Evol Biol       Date:  2010-10-15       Impact factor: 3.260

Review 10.  Targeting angiogenin in therapy of amyotropic lateral sclerosis.

Authors:  Hiroko Kishikawa; David Wu; Guo-fu Hu
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.